03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
01:10 , Nov 10, 2018 |  BC Extra  |  Preclinical News

June highlights shorter CAR T culture times at SITC

In a presentation at the Society for Immunotherapy of Cancer (SITC) meeting Friday, CAR T cell pioneer Carl June highlighted preclinical data from University of Pennsylvania suggesting CAR T cell therapies could require as little...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
23:52 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new target for MM CAR T therapy

In a paper published in Nature Medicine , researchers at Osaka University and colleagues identified activated integrin beta(7) as a new target for a chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, demonstrating...
20:06 , Oct 24, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Nanoparticles; cell therapy Nanoparticles loaded with mRNA could be used for ex vivo programming of patient-derived CAR T cells as cancer therapies. The nanoparticles consist of a biodegradable poly(β-amino ester) polymer core loaded with...
22:41 , Oct 16, 2017 |  BC Extra  |  Preclinical News

Cytokines could predict risk of CAR T neurotoxicities

In a paper published in Cancer Discovery , researchers at the Fred Hutchinson Cancer Research Center and colleagues found that the IL-6 and monocyte chemoattractant protein-1 ( MCP-1 ; CCL2) cytokines could act as early...
18:47 , Mar 17, 2017 |  BioCentury  |  Emerging Company Profile

B-ing persistent

Aleta Biotherapeutics Inc. is extending the use of CD19 -targeting CAR T cells by coating non-B cell tumors with the antigen. President and CSO Paul Rennert told BioCentury the key to effective CAR T cell...
03:48 , Dec 10, 2016 |  BioCentury  |  Product Development

Rules of the road

Investigators and companies have long been devising strategies to mitigate or preempt toxicities from CAR T cell therapies without compromising efficacy. Now, data presented at the American Society of Hematology meeting suggest strategies to prevent...